Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report

被引:15
作者
Huang, Le-Tian [1 ]
Ma, Jie-Tao [1 ]
Zhang, Shu-Ling [1 ]
Li, Xiao-Han [2 ]
Sun, Li [1 ]
Jing, Wei [1 ]
Zhao, Jian-Zhu [1 ]
Wang, Yan-Ru [1 ]
Han, Cheng-Bo [1 ]
机构
[1] China Med Univ, Shengjing Hosp, Dept Oncol, Shenyang, Liaoning, Peoples R China
[2] China Med Univ, Shengjing Hosp, Dept Pathol, Shenyang, Liaoning, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
关键词
apatinib; gastric cancer; HER2; nivolumab; pyrotinib; TYROSINE KINASE INHIBITOR; TRASTUZUMAB RESISTANCE; DOUBLE-BLIND; PTEN; IMMUNOTHERAPY; BIOMARKER; HER2;
D O I
10.3389/fonc.2019.01453
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Patients with advanced gastric cancer, especially the HER2-positive type, have a poor prognosis; there is a paucity of effective anti-HER2 drug therapies in patients who develop resistance to trastuzumab. Case presentation: We report the case of a 36-year-old male with HER2-positive gastric cancer with lung and liver metastases. The patient responded after treatment with trastuzumab combined with chemotherapy and attained a progression-free survival (PFS) of 17 months. Subsequently, the patient received apatinib that selectively inhibits the VEGFR2 and obtained an evident tumor response and a PFS of 8 months. When the disease progressed again, the regimen containing lapatinib failed. Then, the patient received treatment with nivolumab. However, he presented with hyper-progressive disease (HPD). Finally, he received a combination of capecitabine and pyrotinib, an irreversible dual TKI, acting on HER2 and EGFR. The tumor shrank markedly with this combination therapy. The mechanism of both HPD due to immunotherapy and the resistance to trastuzumab and lapatinib were investigated in this case. Loss of phosphatase and tensin homolog (PTEN) and new mutations of BRCA1 and KRAS were detected after resistance to trastuzumab and lapatinib. Conclusions: For patients with HER2-positive advanced gastric cancer who have developed resistance to trastuzumab, pyrotinib is a promising new agent, which can be used as salvage therapy.
引用
收藏
页数:6
相关论文
共 24 条
[1]  
Bang YJ, 2010, LANCET, V376, P1302
[2]   A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].
Berns, Katrien ;
Horlings, Hugo M. ;
Hennessy, Bryan T. ;
Madiredjo, Mandy ;
Hijmans, E. Marielle ;
Beelen, Karin ;
Linn, Sabine C. ;
Gonzalez-Angulo, Ana Maria ;
Stemke-Hale, Katherine ;
Hauptmann, Michael ;
Beijersbergen, Roderick L. ;
Mills, Gordon B. ;
de Vijver, Marc J. van ;
Bernards, Rene .
CANCER CELL, 2007, 12 (04) :395-402
[3]   TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma [J].
Biton, Jerome ;
Mansuet-Lupo, Audrey ;
Pecuchet, Nicolas ;
Alifano, Marco ;
Ouakrim, Hanane ;
Arrondeau, Jennifer ;
Boudou-Rouquette, Pascaline ;
Goldwasser, Francois ;
Leroy, Karen ;
Goc, Jeremy ;
Wislez, Marie ;
Germain, Claire ;
Laurent-Puig, Pierre ;
Dieu-Nosjean, Marie-Caroline ;
Cremer, Isabelle ;
Herbst, Ronald ;
Blons, Helene ;
Damotte, Diane .
CLINICAL CANCER RESEARCH, 2018, 24 (22) :5710-5723
[4]   Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J].
Chan, Arlene ;
Delaloge, Suzette ;
Holmes, Frankie A. ;
Moy, Beverly ;
Iwata, Hiroji ;
Harvey, Vernon J. ;
Robert, Nicholas J. ;
Silovski, Tajana ;
Gokmen, Erhan ;
von Minckwitz, Gunter ;
Ejlertsen, Bent ;
Chia, Stephen K. L. ;
Mansi, Janine ;
Barrios, Carlos H. ;
Gnant, Michael ;
Buyse, Marc ;
Gore, Ira ;
Smith, John, II ;
Harker, Graydon ;
Masuda, Norikazu ;
Petrakova, Katarina ;
Guerrero Zotano, Angel ;
Iannotti, Nicholas ;
Rodriguez, Gladys ;
Tassone, Pierfrancesco ;
Wong, Alvin ;
Bryce, Richard ;
Ye, Yining ;
Yao, Bin ;
Martin, Miguel .
LANCET ONCOLOGY, 2016, 17 (03) :367-377
[5]   Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-A systematic review [J].
Chua, Terence C. ;
Merrett, Neil D. .
INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (12) :2845-2856
[6]  
De Leon J., 2018, CHINA APPROVES HENGR
[7]   Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma [J].
Dong, Zhong-Yi ;
Zhong, Wen-Zhao ;
Zhang, Xu-Chao ;
Su, Jian ;
Xie, Zhi ;
Liu, Si-Yang ;
Tu, Hai-Yan ;
Chen, Hua-Jun ;
Sun, Yue-Li ;
Zhou, Qing ;
Yang, Jin-Ji ;
Yang, Xue-Ning ;
Lin, Jia-Xin ;
Yan, Hong-Hong ;
Zhai, Hao-Ran ;
Yan, Li-Xu ;
Liao, Ri-Qiang ;
Wu, Si-Pei ;
Wu, Yi-Long .
CLINICAL CANCER RESEARCH, 2017, 23 (12) :3012-3024
[8]   Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy [J].
Ferrara, Roberto ;
Mezquita, Laura ;
Texier, Matthieu ;
Lahmar, Jihene ;
Audigier-Valette, Clarisse ;
Tessonnier, Laurent ;
Mazieres, Julien ;
Zalcman, Gerard ;
Brosseau, Solenn ;
Le Moulec, Sylvestre ;
Leroy, Laura ;
Duchemann, Boris ;
Lefebvre, Corentin ;
Veillon, Remi ;
Westeel, Virginie ;
Koscielny, Serge ;
Champiat, Stephane ;
Ferte, Charles ;
Planchard, David ;
Remon, Jordi ;
Boucher, Marie-Eve ;
Gazzah, Anas ;
Adam, Julien ;
Bria, Emilio ;
Tortora, Giampaolo ;
Soria, Jean-Charles ;
Besse, Benjamin ;
Caramella, Caroline .
JAMA ONCOLOGY, 2018, 4 (11) :1543-1552
[9]   HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer [J].
Gomez-Martin, Carlos ;
Garralda, Elena ;
Jose Echarri, M. ;
Ballesteros, Anabel ;
Arcediano, Alberto ;
Luis Rodriguez-Peralto, Jose ;
Hidalgo, Manuel ;
Lopez-Rios, Fernando .
JOURNAL OF CLINICAL PATHOLOGY, 2012, 65 (08) :751-757
[10]   HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target [J].
Gravalos, C. ;
Jimeno, A. .
ANNALS OF ONCOLOGY, 2008, 19 (09) :1523-1529